NCT07559617

Brief Summary

This study evaluates a new ozonated oil-based hair cream for women with oily scalp (seborrhea). The cream contains natural oils (moringa, wheat germ, olive, and chili extract) treated with ozone, plus biotin (vitamin B7). 66 women aged 18-40 years participated in this 6-week study. Participants were randomly assigned to receive either:

  • The active cream (ozonated oils + biotin), OR
  • A placebo cream (without active ingredients) Neither the participants nor the researchers knew which cream was given (double-blind). Participants applied the cream to their scalp every evening for 6 weeks. The main goal was to measure changes in scalp oil (sebum) production at Week 6 compared to baseline. Other outcomes included hair manageability, shine, and scalp comfort. Results showed that the active cream significantly reduced scalp oil by 28% compared to 10% in the placebo group. The cream was well-tolerated with only mild side effects (scalp irritation in 6% of active group). This study suggests that ozonated oil emulsion may be a safe and effective cosmetic option for managing oily scalp in women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 6, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 18, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 18, 2024

Completed
1.9 years until next milestone

First Submitted

Initial submission to the registry

April 16, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

April 30, 2026

Completed
Last Updated

April 30, 2026

Status Verified

April 1, 2026

Enrollment Period

1 month

First QC Date

April 16, 2026

Last Update Submit

April 24, 2026

Conditions

Keywords

Ozonated oilsBiotinOily scalpSeborrheaCosmetic dermatologySebum reduction

Outcome Measures

Primary Outcomes (1)

  • Percent change from baseline in scalp sebum content measured by Sebumeter

    Objective measurement of scalp sebum production using Sebumeter SM 815 (Courage+Khazaka, Germany). Three standardized sites (vertex, left and right parietal regions) measured and averaged. Negative values indicate sebum reduction. Pre-specified clinically meaningful threshold: 15% absolute reduction.

    Baseline (Day 0) and Week 6

Secondary Outcomes (3)

  • Hair shine score (investigator-rated)

    Baseline, Week 2, Week 4, Week 6

  • Scalp comfort score (participant-reported)

    Baseline, Week 2, Week 4, Week 6

  • Investigator Global Assessment success rate

    Week 6

Other Outcomes (4)

  • Adverse event rate

    Throughout 6-week study period

  • Scalp irritation score

    Week 2, Week 4, Week 6

  • Product adherence percentage

    Throughout 6-week study period

  • +1 more other outcomes

Study Arms (2)

Ozonated oil-based cosmetic emulsion

EXPERIMENTAL

Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera, Triticum vulgare, Olea europaea, Capsicum annuum oleoresin) plus biotin 0.1%. Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.

Other: Ozonated oil-based cosmetic emulsion

Matched vehicle control

OTHER

Identical base formulation with caprylic/capric triglyceride and isopropyl palmitate to match total oil phase (8%), rheology, and cosmetic elegance. Same application protocol: 5g evening, overnight, 6 weeks.

Other: Matched vehicle control

Interventions

Low oil-in-water emulsion containing ozonated natural oils (Moringa oleifera 3%, Triticum vulgare 1.95%, Olea europaea 2%, Capsicum annuum oleoresin 0.05%) plus biotin 0.1%. Applied 5g to scalp evening, overnight, rinsed morning for 6 weeks.

Also known as: Ozonated Oil Emulsion
Ozonated oil-based cosmetic emulsion

Identical base formulation with caprylic/capric triglyceride 6% and isopropyl palmitate 2% to match total oil phase (8%), rheology, and cosmetic elegance. Same application protocol: 5g evening, overnight, 6 weeks.

Also known as: Vehicle Control
Matched vehicle control

Eligibility Criteria

Age18 Years - 40 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Female sex (biological), ages 18-40 years
  • Objective sebum measurement ≥200 µg/cm² at baseline (Sebumeter SM 815)
  • Self-reported daily or near-daily hair washing due to oily scalp
  • Willing to abstain from other hair treatments for 2-week washout and study duration
  • Signed informed consent

You may not qualify if:

  • Active scalp dermatoses (psoriasis, atopic dermatitis, tinea capitis) requiring medical treatment
  • Known hypersensitivity to study ingredients or fragrance components
  • Pregnancy, lactation, or planned pregnancy during study period
  • Systemic medications affecting sebum production (isotretinoin, hormonal contraceptives initiated within 3 months, anti-androgens)
  • Participation in other cosmetic or pharmaceutical trials within 30 days

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Research Unit, Syrian Scientific Society for Medicinal Herbs, Aleppo

Aleppo, Syria

Location

MeSH Terms

Conditions

Dermatitis, Seborrheic

Condition Hierarchy (Ancestors)

DermatitisSkin DiseasesSkin and Connective Tissue DiseasesSebaceous Gland DiseasesSkin Diseases, EczematousSkin Diseases, Papulosquamous

Study Officials

  • Hisham M Kasem, Prof.

    Syrian Scientific Society for Medicinal Herbs

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Triple-blind design: participants, investigators, study staff, and statisticians remained masked to treatment assignment throughout the trial. Product identity concealed via identical packaging, appearance, texture, and fragrance-masking.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Double-blind, randomized, placebo-controlled, parallel-group trial with 1:1 allocation ratio and stratification by baseline sebum severity
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 16, 2026

First Posted

April 30, 2026

Study Start

April 6, 2024

Primary Completion

May 18, 2024

Study Completion

May 18, 2024

Last Updated

April 30, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

De-identified participant data, statistical analysis plan, and study protocol will be made available through an established public repository (e.g., Harvard Dataverse, Zenodo, or equivalent) upon publication. Repository selection will be finalized based on technical compatibility and accessibility at the time of data deposit.

Shared Documents
STUDY PROTOCOL, SAP, ANALYTIC CODE
Time Frame
Start Date: Within 6 months of publication End Date: Permanent availability with DOI
Access Criteria
Who: Qualified researchers with methodologically sound proposals What: De-identified participant data (CSV), statistical analysis plan (PDF), study protocol (PDF), and analytic code (SAS/R scripts) How: Submit request via repository platform with brief research proposal. Data use agreement required. Contact corresponding author for access procedures.

Locations